Lv Yanbing, Wu Ruili, Feng Kunrui, Li Jinjie, Mao Qing, Yuan Hang, Shen Huaibin, Chai Xiangdong, Li Lin Song
Key Laboratory for Special Functional Materials of Ministry of Education, Henan University, Kaifeng, 475004, China.
NepQD Biotech Corp, Taizhou, 225300, China.
J Nanobiotechnology. 2017 May 2;15(1):35. doi: 10.1186/s12951-017-0267-4.
The conventional and widely used enzyme-linked immunosorbent assays (ELISA), due to specificity and high-sensitivity, were suitable in vitro diagnosis. But enzymes are vulnerable to the external conditions, and the complex operation steps limit its application. Semiconductor quantum dots have been successfully used in biological and medical research due to the high photoluminescence and high resistance to photobleaching. In this study, we have developed a novel quantum dot-labeled immunosorbent assay for rapid disease detection of C-reactive protein (CRP).
The assay for the detection of CRP can provide a wide analytical range of 1.56-400 ng/mL with the limit of detection (LOD) = 0.46 ng/mL and the limit of quantification = 1.53 ng/mL. The precision of the assay has been confirmed for low coefficient of variation, less than 10% (intra-assay) and less than 15% (inter-assay). The accuracy of assay meets the requirements with the recoveries of 95.4-105.7%. Furthermore, clinical samples have been collected and used for correlation analysis between this FLISA and gold standard Roche immunoturbidimetry. It shows excellent accurate concordance and the correlation coefficient value (R) is as high as 0.989 (n = 34).
This in vitro quantum dot-based detection method offers a lower LOD and a wide liner detection range than ELISA. The total reaction time is only 50 min, which is much shorter than the commercialization ELISA (about 120 min). All of the results show that a convenient, sensitive, and accurate fluorescence-linked immunosorbent assay method has been well established for the detection of CRP samples. Therefore, this method has immense potential for the development of rapid and cost-effective in vitro diagnostic kits.
传统且广泛使用的酶联免疫吸附测定法(ELISA),因其特异性和高灵敏度,适用于体外诊断。但酶易受外部条件影响,且复杂的操作步骤限制了其应用。半导体量子点由于高光致发光性和高抗光漂白性,已成功应用于生物和医学研究。在本研究中,我们开发了一种新型量子点标记免疫吸附测定法,用于快速检测疾病C反应蛋白(CRP)。
检测CRP的测定法可提供1.56 - 400 ng/mL的宽分析范围,检测限(LOD)= 0.46 ng/mL,定量限 = 1.53 ng/mL。该测定法的精密度已通过低变异系数得到证实,批内变异系数小于10%,批间变异系数小于15%。测定法的准确度符合要求,回收率为95.4 - 105.7%。此外,已收集临床样本并用于该荧光免疫测定法(FLISA)与金标准罗氏免疫比浊法之间的相关性分析。结果显示出极佳的准确一致性,相关系数值(R)高达0.989(n = 34)。
这种基于量子点的体外检测方法比ELISA具有更低的检测限和更宽的线性检测范围。总反应时间仅为50分钟,远短于商业化ELISA(约120分钟)。所有结果表明,一种方便、灵敏且准确的荧光免疫吸附测定法已成功建立,用于检测CRP样本。因此,该方法在开发快速且经济高效的体外诊断试剂盒方面具有巨大潜力。